trial · primary record
Ramantamig
Multiple Myeloma
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 230 |
| Primary completion | 2030-07-30 |
| Primary endpoint | Percentage of Participants Alive and Free of Treatment-Emergent American Society for Transplantation and Cellular Therapy (ASTCT) Grade Greater Than or Equal to (>=) 2 Cytokine Release Syndrome (CRS) |
| Registry ID | NCT07589634 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:59:24.491Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07589634
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Ramantamig · compound